<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01553201</url>
  </required_header>
  <id_info>
    <org_study_id>120083</org_study_id>
    <secondary_id>12-N-0083</secondary_id>
    <nct_id>NCT01553201</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin for Pelvic Pain in Women With Endometriosis</brief_title>
  <official_title>The Effectiveness of Botulinum Toxin on Persistent Pelvic Pain in Women With Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Some women with endometriosis have chronic pelvic pain. This pain may be caused by spasms
      of the pelvic floor muscles. These spasms can be detected by an examination. Studies suggest
      that botulinum toxin can help treat problems caused by muscle spasms. Researchers want to see
      if botulinum toxin injections into the pelvic floor muscles can decrease pain and spasms in
      women with pelvic pain.

      Objectives:

      - To see if botulinum toxin can relieve pain from pelvic floor spasm in women with pelvic
      pain.

      Eligibility:

      - Women between 18 and 50 years of age with pain associated with pelvic muscle spasm and
      endometriosis. Pain must be persistent (lasting for at least 3 months).

      Design:

        -  Participants will keep a pain diary and record their pain medication use for a month
           before the first visit.

        -  Participants will be screened with a physical exam and medical history. Blood and urine
           samples will be collected. Participants will also answer questions about their pain
           levels and quality of life.

        -  Participants will receive either botulinum toxin or a placebo (salt water) injection.
           The injection will be given into the pelvic floor muscles through the vaginal wall.
           Participants will take a muscle relaxant like Valium and have anesthetic cream put on
           the vaginal wall before the injection.

        -  After the injection, participants will keep a pain diary for another month.

        -  At a 1-month followup visit, participants will answer questions about their pain. If the
           pain has not improved, all participants may have a botulinum toxin injection (no
           placebo) into the pelvic floor muscles as before.

        -  Participants will have followup visits for up to a year after the initial 1-month
           followup visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic pelvic pain associated with endometriosis is poorly understood. Some women with
      chronic pelvic pain have muscle spasm of their pelvic muscles. Muscle spasm may be a
      significant part of pain in women with endometriosis and other types of chronic pelvic pain.
      Botulinum toxin injection is widely used to treat conditions associated with excessive muscle
      activity and spasm. Studies of botulinum toxin injected into pelvic muscles of women with
      pelvic pain have shown a decrease pain and spasm, but too few women have been studied to
      conclude its effectiveness. We expect to show that botulinum toxin injection in women with
      pelvic pain will relieve some of their pelvic pain.

      Eligible subjects will be otherwise healthy women who have chronic pelvic pain and a history
      of endometriosis. Subjects will be randomized to either botulinum toxin injection or placebo
      (salt water) injection. After one month, we will evaluate the presence of the pain and all
      women will be offered botulinum toxin injection. We will also evaluate the need for
      reinjection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2014</start_date>
  <completion_date type="Actual">July 24, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Improvement in Pain</measure>
    <time_frame>1 month</time_frame>
    <description>Self reported improvement in pain symptoms - a binary measurement of improvement/no improvement</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Endometriosis</condition>
  <condition>Chronic Pelvic Pain</condition>
  <condition>Pelvic Muscle Spasm</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin (BoNT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline, 4cc, one time intramuscular administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin (BoNT)</intervention_name>
    <description>OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration</description>
    <arm_group_label>Botulinum toxin (BoNT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline, 4cc, one time intramuscular administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Female gender

          -  Age between 18 and 55

          -  History of endometriosis at surgery

          -  Persistent pelvic pain for at least 3 months

          -  Pelvic floor spasm

          -  Negative pregnancy test (in women who have not had a hysterectomy)

          -  Willing to use reliable method of contraception for the month after botulinum toxin
             injection including oral contraceptives, IUD, and barrier with spermicide.

          -  Willing and able to give informed consent

          -  Willing and able to comply with study requirements

        EXCLUSION CRITERIA:

          -  Women with other causes of chronic pelvic pain including infectious, gastrointestinal,
             psychological disorders, fibromyalgia and chronic fatigue syndrome based on review of
             medical history within 1 year of first study visit,

          -  Untreated severe cervical dysplasia or other gynecologic condition clinically
             significant abnormalities on physical or laboratory examinations that require
             evaluation or treatment or that would make participation unsafe

          -  Hysterectomy and bilateral salpingo-oophorectomy

          -  Pregnancy

          -  Lactation

          -  Allergy to albumen or botulinum toxin

          -  Presence of antibodies to botulinum toxin or loss of response to previous injections
             for any indication

          -  A known neuromuscular junction disorder such as myasthenia gravis or Eaton-Lambert
             syndrome

          -  History of urinary or fecal incontinence

          -  Known pelvic prolapse

               -  Eligibility will be based on a physical exam at NIH at the first study visit, as
                  well as history and available medical records within 1 year before the study
                  visit. Negative test results will be documented to confirm study eligibility. If
                  the Pap and the GC and chlamydia tests were not done outside of the NIH within
                  the previous year, or if documentation of the negative test results is not
                  available, we will await the results of the screening tests done at the NIH
                  before administering the study medication.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara I Karp, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2012-N-0083.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006 Oct;108(4):915-23.</citation>
    <PMID>17012454</PMID>
  </reference>
  <reference>
    <citation>Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. J Neurol Sci. 2005 Aug 15;235(1-2):1-9. Review.</citation>
    <PMID>15990116</PMID>
  </reference>
  <reference>
    <citation>Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):951-7. Review.</citation>
    <PMID>15201348</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>March 10, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <results_first_submitted>June 30, 2020</results_first_submitted>
  <results_first_submitted_qc>June 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2020</results_first_posted>
  <disposition_first_submitted>April 19, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>June 3, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 6, 2019</disposition_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of Life</keyword>
  <keyword>Endometriosis</keyword>
  <keyword>Botulinum Toxin A</keyword>
  <keyword>Pelvic Floor Muscle Spasm</keyword>
  <keyword>Chronic Pelvic Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Cramp</mesh_term>
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT01553201/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Botulinum Toxin (BoNT)</title>
          <description>OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Saline, 4cc, one time intramuscular administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One subject in the placebo arm completed the study but her data was censored (i.e. not analyzed) on recommendation by the DSMB statistician, as she was one of a sister pair.</population>
      <group_list>
        <group group_id="B1">
          <title>Botulinum Toxin (BoNT)</title>
          <description>OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Saline, 4cc, one time intramuscular administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improvement in Pain</title>
        <description>Self reported improvement in pain symptoms - a binary measurement of improvement/no improvement</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Botulinum Toxin (BoNT)</title>
            <description>OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline, 4cc, one time intramuscular administration</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Pain</title>
          <description>Self reported improvement in pain symptoms - a binary measurement of improvement/no improvement</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Botulinum Toxin (BoNT)</title>
          <description>OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline, 4cc, one time intramuscular administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barbara Karp, MD</name_or_title>
      <organization>National Institute of Neurological Disorders &amp; Stroke</organization>
      <phone>301-496-0150</phone>
      <email>karpb@ninds.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

